Dibromochloromethane

CASRN 124-48-1

  • IRIS Summary (PDF) (13 pp, 116 K)
  • Status: Dibromochloromethane is not being reassessed by IRIS at this time.

Health Hazard Assessments for Effects Other than Cancer


Reference Dose for Oral Exposure (RfD) (PDF) (13 pp, 116 K) last updated: 09/30/1987

RfD (mg/kg-day) System Basis PoD Composite UF Confidence
2 x10-2 Hepatic Hepatic lesions NOEL : 2.14 x101
mg/kg-day
1000 Medium

Reference Concentration for Inhalation Exposure (RfC) (PDF) (13 pp, 116 K)
Not assessed under the IRIS Program.

Cancer Assessment


Weight of Evidence for Cancer (PDF) (13 pp, 116 K) last updated: 01/01/1992

WOE Characterization Framework for WOE Characterization
C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Basis:
  • Based on inadequate human data and limited evidence of carcinogenicity in animals; namely, positive carcinogenic evidence in B6C3Fl mice (males and females), together with positive mutagenicity data, and structural similarity to other trihalomethanes, which are known animal carcinogens.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (13 pp, 116 K)

Oral Slope Factor: 8.4 x10 -2 per mg/kg-day
Drinking Water Unit Risk: 2.4 x10 -6 per µg/L
Extrapolation Method: Linearized multistage procedure, extra risk
Tumor site(s): Hepatic
Tumor type(s): Hepatocellular adenoma or carcinoma (NTP, 1985)


Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (13 pp, 116 K)

Not Assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.